Clinical trial
ZD 1839 Plus Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer
NCT00006049 · AstraZeneca, Industry · Unknown status
Key facts
| NCT number | NCT00006049 |
|---|---|
| Title | ZD 1839 Plus Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer |
| Official title | A Randomized, Double-Blind, Phase III Comparative Trial of 2 Doses of ZD1839 (IRESSA) in Combination With Paclitaxel and Carboplatin Versus Placebo in Combination With Paclitaxel and Carboplatin in Chemotherapy-Naive Patients With Advanced (Stage III or IV) Non-Small Cell Lung Cancer |
| Lead sponsor | AstraZeneca, Industry |
| Status | Unknown status |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Lung Cancer |
| Intervention type | Drug |
| Interventions | carboplatin, gefitinib, paclitaxel |
| Start date | May 1, 2000 |
| First posted | Apr 26, 2004 |
| Last update posted | Dec 19, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: